Table 5.

Association with immune markers, grade and stage

	No. Patients	n (%) with stage III-IV	P-value	n (%) with grade 3	P-value
Overall	55	46 (83.6)		41/54 (75.9)
aPresence with CD3
T-PD-1 + CD3	44	35 (79.5)	0.18	31 (72.1)	0.26
S-PD-1 + CD3	43	34 (79.1)	0.18	34 (81.0)	0.13
Combined PD-1 + CD3	47	38 (80.9)	0.33	34 (73.9)	0.66
PD-L1 + CD3	18	13 (72.2)	0.13	17 (94.4)	0.040
Presence with FoxP3
T-PD-1 + FoxP3	41	33 (80.5)	0.42	30 (75.0)	0.99
S-PD-1 + FoxP3	41	33 (80.5)	0.42	33 (82.5)	0.075
Combined PD-1 + FoxP3	44	36 (81.8)	0.67	33 (76.7)	0.99
PD-L1 + FoxP3	18	13 (72.2)	0.13	17 (94.4)	0.040

^aEvaluation of the association of the presence of PD-1 or PD-L1 together with CD3 and FoxP3 T cells on advanced disease and on high grade tumors. Significant P-values are indicated in italics